On 14 May 2020, Peptonic announced that Peptonic had entered into an agreement regarding the acquisition of a majority of the shares in Lune. The acquisition was completed on 3 June 2020. In connection with the acquisition, Peptonic was granted a call option entitling Peptonic to acquire the remaining shares in Lune from the sellers during the period of three years after closing against a consideration based on the same valuation. Today, Peptonic notified the sellers that Peptonic intends to exercise the call option. The purchase price for the shares amounts to MEUR 1.2 (approx. MSEK 12.5) and payment shall be made in the form of new shares in Peptonic.

The board of directors intends to resolve on an issue of 7 442 774new shares against payment in kind to the sellers, subject to the subsequent approval by the general meeting. The subscription price in the share issue is SEK 1.6822 per share, corresponding to 100% of the volume-weighted average price of Peptonic’s share on Spotlight Stock Market during the period 24^th June 2020 to 7^th July 2020. Payment for the shares shall be made in kind through contribution of 40 shares in Lune. The non-cash consideration is estimated to be recorded in the Company’s balance sheet to a total value of 12 520 031.

The board of directors further intends to convene an extraordinary general meeting during July 2020 with a proposal to approve the board’s resolution to issue the shares to the sellers. An approval of the board’s resolution requires the approval of shareholders representing at least 90 percent of the votes cast as well as the shares represented at the general meeting. 

When the acquisition has been completed, Peptonic will own all outstanding shares in Lune.

Dilution effects and costs

Through the new share issue described above, the share capital increases with in total 744 277.40 SEK through the issue of in total 7 442 774shares. The total number of shares outstanding in the Company after such share issues will amount to 162 586 250 shares. The share issues will thus result in a total dilution effect for existing shareholders of approx. 4.6 percent.

The costs for the share issue to the sellers is expected to amount to approx. 200 TSEK. 

For more information, please contact;

Johan Inborr, CEO

Mobile: +46 708 853 893

E-mail:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7th July, 2020.

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions, and products that contribute to increased sustainability and better quality of life.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.com, ticker: PMED) in Stockholm, Sweden. 

For more information:www.peptonicmedical.com